News Results for Sinclair IS Pharma (SPH)

Christophe Foucher, Executive Director, has transferred in 45,000 shares in the company on the 3rd May 2012 at a price of 1.00p. The Director now holds 156,200 shares. NOTE: Vesting Story...

Sinclair IS Pharma has concluded an early settlement of the earn-out liability with the former shareholders of Cranage Healthcare acquired in December 2010. Under the terms of the earn out, the...

Sinclair IS Pharma reports that revenues increased 67% to £23.4million (H1 11: £14.1m)for the six months to end of December 2011. Like-for-like revenues increased by 9% and there was a...

Story provided by StockMarketWire.com

Sinclair IS Pharma has revealed that revenue for the first half grew by more than 65% to reach approximately £23.4 million The company also reported Like‐for‐like revenue growth of 9% for the six...

Story provided by StockMarketWire.com

Stuart Swanson, Non Executive Director, bought 100,000 shares in the company on the 20th December 2011 at a price of 22.00p. The Director now holds 2,200,000 shares. Story provided by...

Stuart Swanson, Non Executive Director, bought 12,893 shares in the company on the 16th December 2011 at a price of 22.00p. The Director now holds 2,100,000 shares. Story provided by...

Stuart Swanson, Non Executive Director, bought 318,000 shares in the company on the 9th December 2011 at a price of 23.23p. The Director now holds 318,000 shares. Story provided by...

Stuart Swanson, Non Executive Director, bought 318,000 shares in the company on the 9th December 2011 at a price of 23.23p. The Director now holds 318,000 shares. Story provided by...

Stuart Swanson, Non Executive Director, bought 318,000 shares in the company on the 9th December 2011 at a price of 23.23p. The Director now holds 318,000 shares. Story provided by...

Sinclair IS Pharma, the international specialty pharmaceutical company, has completed its acquisition of Advanced Bio-Technologies, a dermatological products company focused on scar treatment and...

Sinclair IS Pharma (LON:SPH), the international specialty pharmaceutical company, has agreed to acquire Advanced Bio-Technologies, a dermatological products company focused on scar treatment and...

Sinclair IS Pharma has announced the disposal of Mysoline for a total cash consideration of �11.1m to Laboratoires SERB SAS, the current distributor of the product in France. The Disposal is...

Story provided by StockMarketWire.com

Sinclair IS Pharma has extended its exclusive agreement with Fannin Limited, the Irish medical sales and distribution company. Under the revised agreement, Fannin will assume responsibility for...

Sinclair IS Pharma plc the international speciality pharma company, today announces its preliminary results for the year ended 30 June 2011 showing total revenue increased 19% to �32.9m (2010:...

Sinclair IS Pharma plc has announced that Board member Grahame Cook will assume the role of Non-Executive Chairman of Sinclair IS effective immediately. Cook succeeds John Gregory who has stepped...

Sinclair IS Pharma said today total revenue increased 19% to �32.9m in the year to end-June (2010: �27.6m), with a loss before tax of �11.7m (2010: loss �18.4m). Like-for-like revenue growth of...

Story provided by StockMarketWire.com

Sinclair IS Pharma's trading update for the twelve months ended 30 June 2011 shows revenues for the full year, are expected to be ahead of expectations at �32.7m following a strong performance by...

Sinclair Pharma is to change its name to Sinclair IS Pharma with immediate effect following the completion of the merger with IS Pharma. Story provided by StockMarketWire.com

Sinclair Pharma plc, the international specialty pharma company, announces the departure of CFO Matthew Hall from the Company with immediate effect. Hall worked at IS Pharma plc alongside CEO...

Following completion of the merger with IS Pharma plc it was proposed that Sinclair Pharma plc change its registered name to Sinclair IS Pharma plc. However the proposed change of registered name...

Further to the announcement earlier this month, Sinclair IS Pharma has confirmed that 139,834,683 New Ordinary Shares have today been admitted to the Official List and to trading on the London...

Story provided by StockMarketWire.com

Jean-Charles Tschudin, Non Executive Director, bought 33,000 shares in the company on the 4th May 2011 at a price of 36.00p. The Director now holds 1,000,117 shares. Story provided by...

Jean-Charles Tschudin, Non Executive Director, bought 56,000 shares in the company on the 28th April 2011 at a price of 36.00p. The Director now holds 967,117 shares. Story provided by...

Drug maker Sinclair Pharma plc and its smaller rival IS Pharma plc have agreed terms on a recommended merger to create Sinclair IS Pharma plc. The deal follows an announcement of advanced merger...

Story provided by StockMarketWire.com

Specialty pharmaceutical company Sinclair Pharma plc has agreed an expanded partnership deal with Invida Holdings Private Limited for the commercialisation of Sinclair's leading brands in India....

International pharmaceutical company Sinclair Pharma plc reported a 28% rise in first-half revenue to �14.1m from �11.0m, up 37% at constant currency. The group reduced its EBITDA loss for the six...

Story provided by StockMarketWire.com

Sinclair Pharma plc and IS Pharma plc announced they are in advanced discussions on a merger to create Sinclair IS Pharma plc, a fully integrated pan-European speciality pharmaceutical company....

Story provided by StockMarketWire.com

Sinclair Pharma reported this morning that revenue for first half to end-December 2010 was up 25% to �13.9m (2009:�11m). Like-for-like revenue growth was 9% for the period following an improved...

Story provided by StockMarketWire.com

Sinclair Pharma plc has formed a partnership with Sunstar Americas Inc. to launch its FDA-approved oral rinse product Decapinol in the US. Launch is planned for 2011. The companies anticipate a...

Story provided by StockMarketWire.com

Specialty pharmaceutical company Sinclair Pharma plc has teamed with Invida Holdings Private Limited to commercialise Sinclair's brands in the Asia Pacific region. Invida is the region's leading...

Story provided by StockMarketWire.com

Story provided by StockMarketWire.com

Sinclair Pharma reported a 47% rise in its first-quarter revenue at constant currency. In an interim management statement for the period from July, Sinclair said like-for-like revenue growth had...

Story provided by StockMarketWire.com

Sinclair Pharma, the speciality pharma company, today reported increased annual losses. For the year ended June 30 2010 operating losses before exceptional items increased from �0.3m. to �3.7m....

Story provided by StockMarketWire.com

Sinclair Pharma says that recent operational performance suggests the underlying business has already improved significantly, with a strong start to the new financial year The Company has acquired...

Story provided by StockMarketWire.com

Speciality pharma company, Sinclair Pharma says that revenues for the year to 30 June 2010 will be 17% ahead of last year and in excess of �27m. The Group reports 23% like-for-like growth from the...

Story provided by StockMarketWire.com

Christopher Spooner, Chief Executive Officer, bought 45,750 shares in the company on the 3rd June 2010 at a price of 27.00p. The Director now holds 6,463,868 shares. NOTE: Story provided by...

Christopher Spooner, Chief Executive Officer, bought 82,000 shares in the company on the 3rd June 2010 at a price of 26.50p. The Director now holds 6,545,868 shares. NOTE: Story provided by...

Christophe Foucher, Executive Director, bought 65,000 shares in the company on the 28th May 2010 at a price of 31.00p. The Director now holds 76,200 shares. NOTE: Euro cents Story provided by...

Christophe Foucher, Executive Director, bought 3,200 shares in the company on the 25th May 2010 at a price of 29.00p. The Director now holds 7,700 shares representing 0.00% of the shares in issue....

Christophe Foucher, Executive Director, bought 3,500 shares in the company on the 25th May 2010 at a price of 28.00p. The Director now holds 11,200 shares. NOTE: Euro cents Story provided by...

Sinclair Pharma plc, the international speciality pharma company, says that the new management's restructuring strategy is driving a significant business turnaround. For the period 1 January to 18...

Syntopix Group has signed an agreement with Sinclair Pharma to work together on the identification of an antimicrobial compound to synergise and augment the activity of a key product for Sinclair....

Sinclair Pharma swung into the red for the six months to December, reporting a pre-exceptionals EBITDA loss of �2.4m against a previous profit of �2.2m. Total revenues were �11.0m, down from...

Story provided by Business Financial Newswire

Sinclair Pharma will announce its half-year financial results for the six months to the end of December on 25 February. Story provided by Business Financial Newswire

Chris Spooner, CEO bought 2,568,140 shares in the company on the 13th January 2010 at a price of 32.00p. The Director now holds 6,418,118 shares representing 4.00% of the shares in issue. NOTE:...

Grahame Cook, Chairman bought 100,000 shares in the company on the 13th January 2010 at a price of 32.00p. The Director now holds 700,000 shares representing 0.40% of the shares in issue. NOTE:...

Jean-Charles Tschudin, Non Executive Director bought 189,997 shares in the company on the 13th January 2010 at a price of 32.00p. The Director now holds 632,388 shares representing 0.40% of the...

Sinclair Pharma has completed the acquisition of the Flammazine and Flammacerium products from Solvay for �17.5m. The products, both topical creams for the prevention and treatment of infections...

Sinclair Pharma has received a 34.8% take-up for its open offer announced on October 29. The remaining shares have been allocated to conditional placees. Chris Spooner, the group's incoming...

Sinclair Pharma chief financial officer Jerry Randall is to step down at the company's EGM in early December to pursue other interests and opportunities. Randall has been in in the position for...

Story provided by Business Financial Newswire

Sinclair Pharma says trading in the first quarter has met management expectations. The acquisition of two revenue-generating products, Flammazine and Flammacerium, from Solvay Pharmaceuticals, is...

Story provided by Business Financial Newswire

Sinclair Pharma has agreed with Orapharma Inc to terminate their distribution agreement for the Impede mouth rinse in the US. As a result, Sinclair says it is free to license and reposition...

Sinclair Pharma has entered new debt facilities of more than �9m plus a �3m facility to replace its existing arrangement. The company's equity fundraising announced on 12 October will be scaled...

Sinclair Pharma reported EBITDA profit before exceptionals of �2.3m, up from �1.3m in 2008, despite revenue flat at �30.4m versus �30.3m. Revenues were impacted by wholesaler de-stocking,...

Sinclair Pharma has acquired two dermatology products from Solvay Pharmaceuticals, Flammazine and Flammacerium, for a total of �17.5m. The products, used to prevention and treat infections in...

Sinclair Pharma said it enjoyed sustained EBITDA profit for the second successive year as the business restructured to focus on commercialisation. In the year to end-June, EBITDA profit before...

Story provided by Business Financial Newswire

Sinclair Pharma has drawn down the remaining �1.3m of its convertible unsecured loan notes. Story provided by Business Financial Newswire

Speciality pharmacuetical company, Sinclair Pharma confirms that it has received an extension on the ability to draw down a further �1.3m under the convertible unsecured loan notes to no later...

Sinclair Pharma says that it it is currently in discussions about a potential significant product acquisition. The Company adds that it would expect to fund this acquisition substantially through...

Sinclair Pharma is to raise �2.3m through the issue of convertible unsecured loan notes to a leading institutional investor. A first series of �1m will be issued immediately with an option to...

Sinclair Pharma says that its treatment for seborrheic dermatitis has now been launched in the United States by Promius Pharma, the dermatology division of Dr Reddy's Laboratories. The Company...

Sinclair Pharma says its revenue for the year ended 30 June is expected to be hit by wholesaler destocking in the face of the economic downturn. However the company says a combination of...

Sinclair Pharma has secured a �10m equity line of credit with GEM Global Yield Fund. CEO Michael Flynn said the three-year agreement would provide Sinclair with alternative working capital if...

Sinclair Pharma moved into the black for the six months to December, with an operating profit of �4.1m after exceptionals against a previous �0.9m operating loss. EBITDA was a positive �2.2m...

Sinclair Pharma has announced a collaboration with US private company BMG Pharma involving two product development and commercialisation deals at a net cost of �0.6 million. It has out-licensed...

Sinclair Pharma has acquired the remaining 49.95% of Spain's Laboratorios Novo Pharma it did not own and is creating a new operating company, Sinclair Pharma Espana. CEO Dr Michael Flynn said,...

Sinclair Pharma and York Pharma have agreed to co-promote selected products to dermatologists and GPs. Sinclair CEO Michael Flynn, CEO says this effectively doubles the specialist salesforce...

Sinclair Pharma said it boosted first-half sales to �10.4m from �9.1m last time on organic sales growth and acquisitions. The company said its pretax first-half loss narrowed to �910,000 from...

Sinclair Pharma reported a wider first-half pretax loss though sales rose 145%. The company said it expects second-half revenues to be 'significantly higher' than those in the first half....

Sinclair Pharma said it expects turnover of �9m for the six months to December 31st, compared with �3.7m one year previously. The speciality pharmaceutical company said results were driven...

Sinclair Pharma reported a small narrowing in annual losses, in line with forecasts. The company has invested in building up its sales force across Europe to distribute its oral and skin care...

Sinclair Pharma said it expects full year operating losses to be narrower than expected and sales to beat analysts' forecasts. This is mainly due to a payment received from US group Chester...

Sinclair Pharma said its oral ulcer treatment Aloclair Rinse will be distributed by Wal-Mart Stores in the US. Wal-Mart has placed its initial order with Sunstar Butler, Sinclair's US sales and...

Sinclair Pharma, the specialty pharmaceutical company, said it has reached agreement with Sunstar Suisse, part of the Sunstar Group, to expand its European agreement for the distribution of...